Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$33.55

52W Range

$22.24 - $46.00

50D Avg

$35.49

200D Avg

$30.50

Market Cap

$2.07B

Avg Vol (3M)

$1.14M

Beta

0.60

Div Yield

-

AGIO Company Profile

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

540

IPO Date

Jul 24, 2013

Website

AGIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25	Dec 24	Dec 23
Product	$54.03M	$36.50M	$26.82M
Royalty	-	-	-

Fiscal year ends in Dec 25 | Currency in USD

AGIO Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$54.03M	$36.50M	$26.82M
Operating Income	$-472.13M	$-425.74M	$-391.49M
Net Income	$-412.78M	$673.73M	$-352.09M
EBITDA	$-472.13M	$-420.08M	$-384.86M
Basic EPS	$-7.12	$11.86	$-6.33
Diluted EPS	$-7.12	$11.64	$-6.33

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q2 26Jul 30, 26 | 8:00 AM

Q1 26Apr 29, 26 | 8:00 AM

Q4 25Feb 12, 26 | 3:00 PM

Peer Comparison

Ticker	Company
GLPG	Galapagos N.V.
RCUS	Arcus Biosciences, Inc.
BEAM	Beam Therapeutics Inc.
COGT	Cogent Biosciences, Inc.
SRPT	Sarepta Therapeutics, Inc.
RXRX	Recursion Pharmaceuticals, Inc.
LQDA	Liquidia Corporation
IBRX	ImmunityBio, Inc.
DNLI	Denali Therapeutics Inc.